The UK’s Life Sciences Innovation Manufacturing Fund, which provides public/private investment to the life sciences industry, has awarded a grant to CDMO Kindeva Drug Delivery. According to a UK government press release, “The investment will create 40 full-time jobs and safeguard 218 existing full-time jobs across Kindeva’s sites in Clitheroe and Loughborough.” Kindeva says that the funds will go toward increased manufacturing capacity for lower-GWP inhalers at its facility in Loughborough and sustainability efforts related to its inhaler component supply chain at Clitheroe.
In November 2021, Kindeva announced that it would install its first lower-GWP MDI filling line for filling either HFA-152a or HFO-1234ze. Several months later, the company announced that it would install a second lower-GWP manufacturing line.
Kindeva Global Chief Commercial Officer David Stevens commented, “This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the UK, as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products. This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”
Read the Kindeva Drug Delivery press release.
Read the UK Government press release.
